Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
- Written by PR Newswire
![]() | ![]() |
- Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population
- In the overall population, elacestrant reduced risk of...